Non-ATP competitive protein kinase inhibitors
L Garuti1, M Roberti, G Bottegoni
1Department of Pharmaceutical Science, University of Bologna, Italy. laura.garuti@unibo.it
Abstract:
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors are ATP-competitive and are called type I inhibitors. The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents. Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC50s measured by biochemical versus cellular assays. The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems. These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function. In the DFG-out form, the phenylalanine side chain moves to a new position. This movement creates a hydrophobic pocket available for occupation by the inhibitor. Some common features are present in these inhibitors. They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue. They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif. Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site. Examples of non ATP-competitive inhibitors are available for various kinases. In this review small molecules capable of inducing the DFG-out conformation are reported, especially focusing on structural feature, SAR and biological properties.
Insights
Non-ATP-competitive kinase inhibitors offer improved selectivity and cellular efficacy over traditional type I inhibitors. This review details small molecules that induce the DFG-out conformation, focusing on structural features and biological properties.
Area of Science:
- Oncology Drug Discovery
- Medicinal Chemistry
- Structural Biology
Background:
- Protein kinases are key targets in cancer therapy.
- ATP-competitive (Type I) inhibitors face challenges with selectivity and cellular activity due to conserved ATP-binding pockets and high intracellular ATP levels.
- Non-ATP-competitive inhibitors (Type II and III) offer potential solutions by inducing conformational changes.
Purpose of the Study:
- To review small molecules that induce the DFG-out kinase conformation.
- To focus on the structural features, structure-activity relationships (SAR), and biological properties of these inhibitors.
Main Methods:
- Literature review of non-ATP-competitive kinase inhibitors.
- Analysis of structural characteristics, including hinge-binding moieties, hydrophobic pockets, and allosteric site interactions.
- Examination of structure-activity relationships (SAR) and biological data.
Main Results:
- Non-ATP-competitive inhibitors induce a DFG-out conformation, creating an allosteric pocket.
- These inhibitors typically feature a heterocyclic system for hinge binding and a hydrophobic moiety for the allosteric pocket.
- A linker, often urea or amide, connects these features and interacts with the allosteric site.
Conclusions:
- Non-ATP-competitive inhibitors represent a promising strategy for developing selective and effective kinase-targeted cancer therapies.
- Understanding the structural requirements for DFG-out induction is crucial for rational drug design.
- These inhibitors can overcome limitations associated with ATP-competitive agents.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
ATP Synthase: Mechanism
Enzyme Inhibition
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...


